- Home
- DERM vs ENTA Comparison
DERM vs ENTA Comparison
Compare DERM & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DERM
- ENTA
- Stock Information
- Founded
- DERM 2014
- ENTA 1995
- Country
- DERM United States
- ENTA United States
- Employees
- DERM N/A
- ENTA N/A
- Industry
- DERM Biotechnology: Pharmaceutical Preparations
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- DERM Health Care
- ENTA Health Care
- Exchange
- DERM Nasdaq
- ENTA Nasdaq
- Market Cap
- DERM 174.7M
- ENTA 154.0M
- IPO Year
- DERM 2021
- ENTA 2013
- Fundamental
- Price
- DERM $6.88
- ENTA $5.27
- Analyst Decision
- DERM Strong Buy
- ENTA Buy
- Analyst Count
- DERM 2
- ENTA 4
- Target Price
- DERM $10.00
- ENTA $17.25
- AVG Volume (30 Days)
- DERM 78.2K
- ENTA 194.0K
- Earning Date
- DERM 05-20-2025
- ENTA 05-20-2025
- Dividend Yield
- DERM N/A
- ENTA N/A
- EPS Growth
- DERM N/A
- ENTA N/A
- EPS
- DERM N/A
- ENTA N/A
- Revenue
- DERM $56,134,000.00
- ENTA $66,590,999.00
- Revenue This Year
- DERM $29.83
- ENTA N/A
- Revenue Next Year
- DERM $54.88
- ENTA N/A
- P/E Ratio
- DERM N/A
- ENTA N/A
- Revenue Growth
- DERM N/A
- ENTA N/A
- 52 Week Low
- DERM $3.20
- ENTA $4.09
- 52 Week High
- DERM $7.84
- ENTA $17.24
- Technical
- Relative Strength Index (RSI)
- DERM 52.73
- ENTA 45.38
- Support Level
- DERM $6.47
- ENTA $4.96
- Resistance Level
- DERM $7.15
- ENTA $6.23
- Average True Range (ATR)
- DERM 0.49
- ENTA 0.33
- MACD
- DERM -0.09
- ENTA -0.01
- Stochastic Oscillator
- DERM 37.25
- ENTA 24.41
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.